Unmet Needs and the Future of AML Treatment
Eytan Stein, MD and Hetty Carraway, MD, wrap up their discussion with a review of the unmet needs in AML treatment and exciting therapies in the pipeline.
The Importance of Bone Marrow Biopsies in AML Patients on Venetoclax Treatment
Hetty Carraway, MD, explains the importance of bone marrow biopsies in patients with AML receiving treatment with venetoclax + azacitidine.
Management of Cytopenia in Patients on Venetoclax + Azacitidine Therapy
Hetty Carraway, MD and Eytan Stein, MD, discuss the appropriate strategies for the management of cytopenias in patients with AML on venetoclax + azacitidine treatment.
Case Presentation: An 81-Year-Old Male with AML
Eytan Stein, MD, presents the case of an 81-year-old patient with AML who is unfit for intensive induction therapy for discussion.
Treatment of Patients Unfit for Intensive Induction with Venetoclax + Azacitidine
Hetty Carraway, MD, highlights the role of venetoclax + azacitidine in the treatment of patients with acute myeloid leukemia who are unfit for intensive induction therapy.
Treatment Options for AML Patients with IDH2, RUNX1, or DNMT3A Mutations
Eytan Stein, MD, continues the discussion of AML treatments with a look at the options for patients with AML and mutations.
Treatment Options for Secondary AML
Eytan Stein, MD, reviews the available treatment options for patients with secondary AML or AML with myelodysplasia-related changes.
Intensive Induction Therapy In AML
Hetty Carraway, MD, describes the criteria used to determine if a patient with newly-diagnosed acute myeloid leukemia is suitable for intensive induction therapy.
Frontline Treatment Options for Patients with AML
Eytan Stein, MD, provides an overview of the frontline treatment options currently available for acute myeloid leukemia.
Overview of Acute Myeloid Leukemia (AML)
Eytan Stein, MD, provides a brief overview of acute myeloid leukemia.
Dr. Eytan Stein on Multiple Targets in Acute Myeloid Leukemia
Eytan Stein, MD, discusses targeting multiple mutations in patients with acute myeloid leukemia (AML).
Dr. Eytan Stein on Targeting Mutations in Acute Myeloid Leukemia
Eytan Stein, MD, discusses the benefits of being able to identify drivers in acute myeloid leukemia and having drugs coming into the clinics to target those biological mutations.
2 Clarke Drive Cranbury, NJ 08512